Athera Biotechnologies has released the results of a study which linked the low levels of plasma anti-PC, measured with Athera's CVDefine kit, to a high risk of vein graft failure after bypass surgery.
The report is based on the data collected from the observational study conducted by professor Michael Sobel, VA Puget Sound HCS and the University of Washington in patients undergoing vein bypasses for atherosclerotic occlusive disease of the legs.
The objective of the study was to determine whether low anti-PC antibody levels might be associated with loss of primary patency using Athera's CVDefine kit.
Athera CEO Carina Schmidt said Athera is developing an anti-inflammatory antibody therapy, PC-mAb to prevent secondary cardiovascular events in myocardial infarction patients with low levels of anti-PC.
''These new findings may open opportunities for PC-mAb and its companion diagnostic kit CVDefine?, for identification and treatment of a high-risk patient group in a niche indication of high medical need," Schmidt added.
The company presented the report at the Pacific Northwest Vascular Society Annual Meeting in Vancouver, Canada.